Noninvasive evaluation of mucosal healing in inflammatory bowel diseases

Jun Kato, Sakiko Hiraoka, Asuka Nakarai, Masao Ichinose

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Current opinions increasingly cite the need to achieve not only clinical response but also endoscopic mucosal healing in the treatment of both types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). Although endoscopic procedures are necessary for confirmation of mucosal healing, undergoing colonoscopy is invasive and burdensome to patients. Therefore, alternative noninvasive methods of evaluating or predicting mucosal status have been eagerly desired. For this purpose, blood, fecal, and radiologic modalities have been suggested and examined. C-reactive protein and fecal markers such as fecal calprotectin can evaluate active inflammation to some extent in both UC and CD. However, their predictive values for mucosal healing have not yet been fully evaluated and current knowledge indicates that the values were rather insufficient. Radiologic modalities such as computed tomography, magnetic resonance, and ultrasound can also evaluate mucosal inflammation but are currently not suitable for detection of healing. Capsule endoscopy may be optimal for evaluating mucosal status of the small bowel in CD patients, but sufficient data are not yet available, particularly for mucosal healing. Thus, these candidates for the surrogate modality are currently imperfect for evaluation of mucosal healing, but the changes in values/findings of these modalities after initiation of therapy appear to be rather promising as a marker of efficacy of the therapy. Finally, our recent data showed that a fecal immunochemical test for evaluation of mucosal healing in UC was very promising and this method should be further evaluated in CD also.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalClinical Journal of Gastroenterology
Volume6
Issue number1
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Inflammatory Bowel Diseases
Crohn Disease
Ulcerative Colitis
Leukocyte L1 Antigen Complex
Inflammation
Capsule Endoscopy
Colonoscopy
C-Reactive Protein
Magnetic Resonance Spectroscopy
Therapeutics
Tomography

Keywords

  • C-reactive protein
  • Crohn's disease
  • Endoscopy
  • Fecal immunochemical test
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Noninvasive evaluation of mucosal healing in inflammatory bowel diseases. / Kato, Jun; Hiraoka, Sakiko; Nakarai, Asuka; Ichinose, Masao.

In: Clinical Journal of Gastroenterology, Vol. 6, No. 1, 02.2013, p. 1-7.

Research output: Contribution to journalArticle

Kato, Jun ; Hiraoka, Sakiko ; Nakarai, Asuka ; Ichinose, Masao. / Noninvasive evaluation of mucosal healing in inflammatory bowel diseases. In: Clinical Journal of Gastroenterology. 2013 ; Vol. 6, No. 1. pp. 1-7.
@article{7d892a7933534aba864a0b227cc73ca0,
title = "Noninvasive evaluation of mucosal healing in inflammatory bowel diseases",
abstract = "Current opinions increasingly cite the need to achieve not only clinical response but also endoscopic mucosal healing in the treatment of both types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). Although endoscopic procedures are necessary for confirmation of mucosal healing, undergoing colonoscopy is invasive and burdensome to patients. Therefore, alternative noninvasive methods of evaluating or predicting mucosal status have been eagerly desired. For this purpose, blood, fecal, and radiologic modalities have been suggested and examined. C-reactive protein and fecal markers such as fecal calprotectin can evaluate active inflammation to some extent in both UC and CD. However, their predictive values for mucosal healing have not yet been fully evaluated and current knowledge indicates that the values were rather insufficient. Radiologic modalities such as computed tomography, magnetic resonance, and ultrasound can also evaluate mucosal inflammation but are currently not suitable for detection of healing. Capsule endoscopy may be optimal for evaluating mucosal status of the small bowel in CD patients, but sufficient data are not yet available, particularly for mucosal healing. Thus, these candidates for the surrogate modality are currently imperfect for evaluation of mucosal healing, but the changes in values/findings of these modalities after initiation of therapy appear to be rather promising as a marker of efficacy of the therapy. Finally, our recent data showed that a fecal immunochemical test for evaluation of mucosal healing in UC was very promising and this method should be further evaluated in CD also.",
keywords = "C-reactive protein, Crohn's disease, Endoscopy, Fecal immunochemical test, Ulcerative colitis",
author = "Jun Kato and Sakiko Hiraoka and Asuka Nakarai and Masao Ichinose",
year = "2013",
month = "2",
doi = "10.1007/s12328-012-0346-x",
language = "English",
volume = "6",
pages = "1--7",
journal = "Clinical Journal of Gastroenterology",
issn = "1865-7257",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Noninvasive evaluation of mucosal healing in inflammatory bowel diseases

AU - Kato, Jun

AU - Hiraoka, Sakiko

AU - Nakarai, Asuka

AU - Ichinose, Masao

PY - 2013/2

Y1 - 2013/2

N2 - Current opinions increasingly cite the need to achieve not only clinical response but also endoscopic mucosal healing in the treatment of both types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). Although endoscopic procedures are necessary for confirmation of mucosal healing, undergoing colonoscopy is invasive and burdensome to patients. Therefore, alternative noninvasive methods of evaluating or predicting mucosal status have been eagerly desired. For this purpose, blood, fecal, and radiologic modalities have been suggested and examined. C-reactive protein and fecal markers such as fecal calprotectin can evaluate active inflammation to some extent in both UC and CD. However, their predictive values for mucosal healing have not yet been fully evaluated and current knowledge indicates that the values were rather insufficient. Radiologic modalities such as computed tomography, magnetic resonance, and ultrasound can also evaluate mucosal inflammation but are currently not suitable for detection of healing. Capsule endoscopy may be optimal for evaluating mucosal status of the small bowel in CD patients, but sufficient data are not yet available, particularly for mucosal healing. Thus, these candidates for the surrogate modality are currently imperfect for evaluation of mucosal healing, but the changes in values/findings of these modalities after initiation of therapy appear to be rather promising as a marker of efficacy of the therapy. Finally, our recent data showed that a fecal immunochemical test for evaluation of mucosal healing in UC was very promising and this method should be further evaluated in CD also.

AB - Current opinions increasingly cite the need to achieve not only clinical response but also endoscopic mucosal healing in the treatment of both types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). Although endoscopic procedures are necessary for confirmation of mucosal healing, undergoing colonoscopy is invasive and burdensome to patients. Therefore, alternative noninvasive methods of evaluating or predicting mucosal status have been eagerly desired. For this purpose, blood, fecal, and radiologic modalities have been suggested and examined. C-reactive protein and fecal markers such as fecal calprotectin can evaluate active inflammation to some extent in both UC and CD. However, their predictive values for mucosal healing have not yet been fully evaluated and current knowledge indicates that the values were rather insufficient. Radiologic modalities such as computed tomography, magnetic resonance, and ultrasound can also evaluate mucosal inflammation but are currently not suitable for detection of healing. Capsule endoscopy may be optimal for evaluating mucosal status of the small bowel in CD patients, but sufficient data are not yet available, particularly for mucosal healing. Thus, these candidates for the surrogate modality are currently imperfect for evaluation of mucosal healing, but the changes in values/findings of these modalities after initiation of therapy appear to be rather promising as a marker of efficacy of the therapy. Finally, our recent data showed that a fecal immunochemical test for evaluation of mucosal healing in UC was very promising and this method should be further evaluated in CD also.

KW - C-reactive protein

KW - Crohn's disease

KW - Endoscopy

KW - Fecal immunochemical test

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84873410703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873410703&partnerID=8YFLogxK

U2 - 10.1007/s12328-012-0346-x

DO - 10.1007/s12328-012-0346-x

M3 - Article

AN - SCOPUS:84873410703

VL - 6

SP - 1

EP - 7

JO - Clinical Journal of Gastroenterology

JF - Clinical Journal of Gastroenterology

SN - 1865-7257

IS - 1

ER -